At the 2026 meeting of the American Association for Pediatric Ophthalmology and Strabismus, Sydnexis reported new subgroup analyses from the phase 3 Study of Atropine for the Reduction of Myopia Progression trial evaluating SYD-101 0.01% in pediatric progressive myopia. According to the company, the trial enrolled 847 children aged 3 to 14 years across 47 sites in the United States and Europe, making it the largest completed global clinical program in pediatric myopia to date.

In the overall study population, SYD-101 0.01% met the primary efficacy endpoint and a key secondary endpoint. The company said the treatment significantly reduced confirmed myopia progression of -0.75 D or worse at 36 months vs vehicle (P = .0226) and reduced mean annual progression rate at 12, 24, and 36 months. At month 36, the annual progression rate was -0.30 D/year with SYD-101 0.01% vs -0.38 D/year with vehicle (P < .001).

The subgroup analyses suggested the greatest treatment effect occurred in younger children and in those with faster progression and less severe baseline myopia. In children aged 3 to 12 years at treatment initiation, myopia progression was reduced by 47.9% at 12 months, 37.6% at 24 months, and 28.0% at 36 months vs vehicle; children aged 13 to 14 years showed minimal progression regardless of treatment. The largest benefit was reported in children with fast progression of more than 0.5 D/year and baseline myopia of -0.50 to -3.00 D, with progression reduced by 76.3% at 12 months, 65.1% at 24 months, and 56.9% at 36 months vs vehicle (-1.18 D vs -0.51 D at 36 months; P = .0004).

Sydnexis also reported that SYD-101 was well tolerated, with no unexpected atropine-related adverse events. The company said these findings support earlier identification and intervention in children most likely to benefit, particularly those aged 3 to 12 years with mild to moderate myopia and faster documented progression.